Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
MiT family translocation renal cell carcinoma (t-RCC) is a rare subtype of renal cell carcinoma with recurrent genetic abnormalities, harboring rearrangements of the TFE3 (Xp11 t-RCC) or TFEB [t(6;11) t-RCC] genes. The t(6;11) t-RCC has distinctive histologic features of biphasic appearance with larger epitheloid and smaller eosinophilic cells. The symptoms are usually non-specific and include hematuria, flank pain, palpable abdominal mass and/or systemic symptoms of anemia, fatigue and fever.
Biomarker and diagnostic research for MIT family translocation renal cell carcinoma has been reported in the published literature.
5 clinical trials registered, 3 recruiting. Interventions under study include drug therapy and biologic therapy. Pipeline includes 3 PHASE2, 1 PHASE1, 1 EARLY_PHASE1. Research is primarily sponsored by academic and government institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT04413123](https://clinicaltrials.gov/study/NCT04413123) |
Data assembled from 4 of 12 sources · Last updated Sep 20, 2026, 3:14 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about MIT family translocation renal cell carcinoma
Cabozantinib In Combo With NIVO + IPI In Advanced NCCRCC
PHASE2 |
Bradley A. McGregor, MD |
ACTIVE_NOT_RECRUITING |
[NCT06318871](https://clinicaltrials.gov/study/NCT06318871) | Memory-like Natural Killer (NK) Cell Therapy in Patients With Renal Cell Carcinoma or Urothelial Carcinoma | EARLY_PHASE1 | Dana-Farber Cancer Institute | ACTIVE_NOT_RECRUITING |
[NCT07123090](https://clinicaltrials.gov/study/NCT07123090) | A Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma | PHASE2 | Stephanie Berg | RECRUITING |
[NCT06835972](https://clinicaltrials.gov/study/NCT06835972) | A Study of Abemaciclib and Cabozantinib in People With Clear Cell Renal Cell Carcinoma (ccRCC) | PHASE1 | Memorial Sloan Kettering Cancer Center | RECRUITING |
[NCT06638931](https://clinicaltrials.gov/study/NCT06638931) | Agnostic Therapy in Rare Solid Tumors | PHASE2 | Instituto do Cancer do Estado de São Paulo | RECRUITING |
45 publications have been identified in PubMed for MIT family translocation renal cell carcinoma. Research spans Basic Science / Preclinical (49%), Case Report / Case Series (24%), and Review / Meta-Analysis (11%).
Research Type | Count | % of Total |
|---|---|---|
Laboratory research | 22 | 49% |
Patient case studies | 11 | 24% |
Research summaries | 5 | 11% |
Testing and diagnosis research | 4 | 9% |
Clinical study results | 2 | 4% |
New treatment approaches | 1 | 2% |
Ito K (2026). [PMID: 41623175](https://pubmed.ncbi.nlm.nih.gov/41623175/). *The Journal of clinical investigation*. [Diagnostic / Biomarker]
Groenendijk A (2026). [PMID: 42193282](https://pubmed.ncbi.nlm.nih.gov/42193282/). *Biomedicines*. [Basic Science / Preclinical]
Portu M (2026). [PMID: 41899560](https://pubmed.ncbi.nlm.nih.gov/41899560/). *Cancers*. [Review / Meta-Analysis]
Liu Y (2026). [PMID: 41930555](https://pubmed.ncbi.nlm.nih.gov/41930555/). *Cancer treatment and research communications*. [Diagnostic / Biomarker]
Zhou Z (2026). [PMID: 41885733](https://pubmed.ncbi.nlm.nih.gov/41885733/). *International journal of surgical pathology*. [Case Report / Case Series]
Li H (2026). [PMID: 41178060](https://pubmed.ncbi.nlm.nih.gov/41178060/). *The Journal of pathology*. [Basic Science / Preclinical]
Garinet S (2026). [PMID: 41623182](https://pubmed.ncbi.nlm.nih.gov/41623182/). *The Journal of clinical investigation*. [Case Report / Case Series]
Argani P (2026). [PMID: 41384707](https://pubmed.ncbi.nlm.nih.gov/41384707/). *Histopathology*. [Review / Meta-Analysis]
Zhang KJ (2026). [PMID: 41633656](https://pubmed.ncbi.nlm.nih.gov/41633656/). *Annals of clinical and laboratory science*. [Review / Meta-Analysis]
Li J (2025). [PMID: 39915638](https://pubmed.ncbi.nlm.nih.gov/39915638/). *Nature metabolism*. [Basic Science / Preclinical]